Results 171 to 180 of about 112,622 (301)

PARP Inhibitor E7016 [PDF]

, 2020
openaire   +1 more source

In‐Tumor CRISPR‐Cas9 Knockout Screening and Novel Therapy Development for Malignant Transformation of Ovarian Teratoma

Cancer Science, EarlyView.
We conducted an in vivo genome‐wide CRISPR‐Cas9 knockout screen using MTMCT‐derived cells to identify genes essential for tumor growth. SOD1 emerged as a key therapeutic target, and its inhibition suppressed tumor proliferation by disrupting redox homeostasis, both in vitro and in PDX models. ABSTRACT Malignant transformation of mature cystic teratoma (
Satoshi Tamauchi, Kosuke Yoshida, Wang Xinyuan, Atsushi Nakagawa, Akira Yokoi, Nobuhisa Yoshikawa, Kaoru Niimi, Yusuke Yamamoto, Hiroaki Kajiyama   +8 more
wiley   +1 more source

Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. [PDF]

Cancer Biol Ther
Tomas EJ, Davis J, Ramos Valdes Y, Shepherd TG.   +3 more
europepmc   +1 more source

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2‐Positive Cancers

Cancer Science, EarlyView.
Overexpression of ABC transporters, especially ABCG2 and ABCB1, mediates acquired resistance to T‐DXd in HER2‐positive cancers. Inhibition of these transporters restored T‐DXd efficacy, highlighting efflux‐mediated resistance as a potential therapeutic target. ABSTRACT Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer
Yuya Murase, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda, Shigeki Sato, Jun Kinoshita, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura, Yuichi Tambo, Takahiro Shimizu, Masafumi Horie, Daichi Maeda, Richard W. Wong, Kazuyoshi Hosomichi, Takafumi Kobayashi, Satoshi Watanabe, Kenta Yamamura, Noriyuki Ohkura, Miki Abo, Seiji Yano   +23 more
wiley   +1 more source

Intersecting Anemias: PARP Inhibitor-Induced Toxicity and Autoimmune Hemolysis-A Case Report. [PDF]

EJHaem
Dereme J, Asonitis K, Grandoni F, Liapi A, Sarivalasis A, Tsilimidos G.   +5 more
europepmc   +1 more source

IAP Antagonists Selectively Eliminate Therapy‐Induced Senescent Cancer Cells via TNFα‐Independent Apoptosis

Cancer Science, EarlyView.
Upon chemotherapy, a subset of cancer cells enters a senescent state, referred to as TIS. When IAP antagonists are administered, TIS cells are selectively eliminated through TNFα‐independent apoptosis. TNFα secreted by TIS cancer cells may also act in a paracrine manner to enhance extrinsic apoptosis in neighboring non‐senescent cancer cells.
Hiroaki Ochiiwa, Takeshi Wakasa, Yuki Kataoka, Koji Ando, Eiji Oki, Yoshihiko Maehara, Makoto Iimori, Hiroyuki Kitao   +7 more
wiley   +1 more source

GSK3β guides chromosomal repair pathway selection to support BRCA1-independent PARP inhibitor sensitivity. [PDF]

J Clin Invest
Leung JW, Gius D.
europepmc   +1 more source

PARP Inhibitor AZD2461 [PDF]

, 2020
openaire   +1 more source

A novel glucose beta‐hydroxybutyrate combination improves hypoglycaemia recovery and patient‐reported outcomes in type 1 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Hypoglycaemia remains a major barrier to optimal diabetes management. Current treatments based on simple sugars have limitations, including rapid glucose fluctuations and persistent neuroglycopenic symptoms. We investigated FLO23011, a novel multi‐substrate energy formulation containing glucose and beta‐hydroxybutyrate, as a superior ...
D. Russell‐Jones, V. Smout, S. Roy, G. Myers, R. Littlewood, F. Shojaee‐Moradie   +5 more
wiley   +1 more source

PARP Inhibitors in Lung Cancer [PDF]

Journal of Thoracic Oncology, 2012
openaire   +2 more sources